Avalo Therapeutics, Inc.

NasdaqCM:AVTX Stock Report

Mkt Cap: US$46.1m

Avalo Therapeutics Future Growth

How is Avalo Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


38.6%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

NasdaqCM:AVTX - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202549-190404
12/31/202435-1723444
12/31/20238-50-41-514
9/30/202217-51-40-40N/A
6/30/20224-72-62-62N/A
3/31/20226-76-69-69N/A
12/31/20215-84-71-71N/A
9/30/20217-81-68-68N/A
6/30/20216-77-64-64N/A
3/31/20214-73-53-53N/A
12/31/20207-64-41-41N/A
9/30/20206-54-28-28N/A
6/30/20207-44-24-24N/A
3/31/20207-33-22-22N/A
12/31/20197-16-19-19N/A
9/30/20190-13-20-19N/A
6/30/20192-35-13-12N/A
3/31/20195-38-7-6N/A
12/31/20187-37-4-3N/A
9/30/201816-42-4-4N/A
6/30/20183721616N/A
3/31/20183261415N/A
12/31/20172881313N/A
9/30/201726131111N/A
6/30/20171-12-11-11N/A
3/31/20172-13-13-13N/A
12/31/20161-16-15-15N/A
9/30/20161-18-14-14N/A
6/30/20161-13N/A-13N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: AVTX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: AVTX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: AVTX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: AVTX's revenue (41.3% per year) is forecast to grow faster than the US market (6.8% per year).

High Growth Revenue: AVTX's revenue (41.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if AVTX's Return on Equity is forecast to be high in 3 years time


Discover growth companies